07 Nov IVDR certification achieved for DPYD genotyping assay – One of the first products of its kind to conform with new IVDR requirements
Posted at 08:02h
in Uncategorized
Paris, France, and Eastleigh and Manchester, UK – 7 November 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, confirms IVDR accreditation under the new EU requirements of the In Vitro Diagnostic Regulation (“IVDR”) for its DPYD genotyping assay, which supports the identification of cancer patients at risk of suffering a severe, and potentially life-threatening, reaction to common chemotherapy.